Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve (CENTERA-1)
Status
Conditions
Treatments
Details and patient eligibility
About
The purpose of this study is to assess the safety and device success of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe aortic stenosis who are indicated for aortic valve replacement.
Full description
This is a non-randomized, prospective, multi-center safety and device success study. 34 patients have been enrolled at 4 participating investigational centers in Europe. Patient participation will last for a minimum of 5 years. Patients will be assessed at the following intervals: baseline, discharge, 30 days, 6 months, 1 year and annually thereafter through 5 years
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- High surgical risk: STS Score ≥ 8,EuroSCORE ≥ 15.
- NYHA ≥ II.
- Heart team (including examining cardiac surgeon) agrees on eligibility including assessment that TAVR is appropriate.
- Study patient is an adult of legal consent age.
- Study patient has provided written informed consent to comply with all of the study procedures and follow-up visits.
Exclusion criteria
- Acute myocardial infarction ≤ 30 days before the intended treatment.
- Untreated clinically significant coronary artery disease requiring revascularization.
- Aortic valve is a congenital unicuspid or congenital bicuspid valve.
- Mixed aortic valve disease (with predominant aortic regurgitation).
Trial design
Primary purpose
Allocation
Interventional model
Masking
34 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal